Immunis, Inc.
Wednesday, June 05, 2024
Company Presentation
![Cell and Gene Therapy and Genome Editing](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/BIO-track-icon_GeneEditing_MTC.png)
Company Presentation Theater 1
Immunis is a private biotechnology company researching and developing secretome products to address age-driven immune dysfunction. Our investigational secretome product, IMMUNA, leverages our leading-edge capabilities in cell culture to deliver a product of all natural, all human immune modulators in their natural relative concentrations. Immunis is currently testing the effects of IMMUNA in a Phase 1/2a clinical trial for muscle atrophy.
![Immunis, Inc.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1716587-1-JPG.png)
Company Website:
http://www.immunisbiomedical.com
Lead Product in Development:
IMMUNA (formerly known as IMM01-STEM)
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Company HQ City
Irvine
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
Hans Keirstead, PhD
Development Phase of Primary Product
Phase I
Primary Speaker